Mussa H. Almalki, Nora Nasser Aljoaib, Maha Jurais Alotaibi, Bayan Saloum Aldabas, Tayba Saleh Wahedi, Maswood M. Ahmad, Fahad Alshahrani
Pituitary tumors represent 10-15% of all intracranial tumors; of these, prolactinomas account for 40-50% of cases. Prolactinomas usually respond well to dopamine agonists (DA) as first-line therapy. However, treatment resistance remains a concern. Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas …